Navigation Links
Alfacell Corporation to Present at UBS Global Life Sciences Conference
Date:9/19/2007

SOMERSET, N.J., Sept. 19 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 8:30 a.m. EDT on Sept. 26, 2007, at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City.

The live Webcast of the presentation will be available on Alfacell's Web site at http://www.alfacell.com. A replay of the Webcast will be available online for 30 days.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4253

david.schull@russopartnersllc.com andreas.marathis@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
9. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
10. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
11. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2019)... ... 15, 2019 , ... RMA of Connecticut, a leading fertility practice whose exceptional ... informational event that will demystify fertility age-related issues and will include complimentary fertility ... Real Fertility Age ,” will take place on Thursday, January 24th at 6 PM ...
(Date:1/15/2019)... MALVERN, Pa. (PRWEB) , ... January 15, 2019 ... ... today announced twelve new course locations for the 2019 Wound Certification Prep Course ... for clinicians to possess increased specialized knowledge in wound management, WCPC will be ...
(Date:1/15/2019)... ... January 15, 2019 , ... ... Texas Health Resources (THR), the largest faith-based nonprofit health system in North ... hospitals. According to MDsyncNET Co-Founder and CEO Brad Goldsmith, “We’re committed to ...
Breaking Medicine Technology:
(Date:1/11/2019)... ... , ... Women’s Excellence specializes in the excision of endometriosis, ... help restore fertility. , Endometriosis is a disease in which endometrial tissue grows ... ovaries, fallopian tubes, and the inner lining of the abdomen.  In more severe ...
(Date:1/10/2019)... ... January 10, 2019 , ... On Tuesday, January 8, Dr. Samuel Joseph, Jr. , ... world to use Osseus Fusion Systems revolutionary 3D Printed Aries Titanium Spinal ... and see your ideas brought to life so quickly,” commented Dr. Joseph, founder of Joseph ...
(Date:1/10/2019)... ... January 10, 2019 , ... The Karis Group, an Austin, Texas based company, ... Chief Executive Officer effective immediately. Mr. Jiwa succeeds the past Chief Executive Officer, ... The transition was announced as part of an orderly succession plan and transition ...
(Date:1/10/2019)... ... January 10, 2019 , ... JWRX, ... companies, partners with NeuCana Companion to educate dog owners on CBD and hemp ... to help calm pain and anxiety related ailments by supporting a pet’s endocannabinoid ...
(Date:1/8/2019)... ... , ... Cigna-HealthSpring’s Medicare Advantage (MA) customers in or near ... new option for their medical care with the addition of JenCare Senior ... in Atlanta that provide access to primary care physicians and specialist doctors, including ...
Breaking Medicine News(10 mins):